CB21 / Cartography Biosci - LARVOL DELTA

LY6G6D targeting with a T cell engager is a promising therapeutic for MSS colorectal cancer (AACR 2025) - "An accelerated phase I clinical plan is presented.Utilizing our ATLAS platform, we identified LY6G6D as the most promising target in MSS CRC due to its specific expression in malignant cells, high antigen surface stability, and persistence in both primary and metastatic CRC. The data presented support that the CB21 TCE has been meticulously engineered to be a potentially first and best-in-class TCE targeting LY6G6D."

Colorectal Cancer • Oncology • Solid Tumor • LY6G6D • MSI

A CB21-targeted T cell engager is a promising therapeutic for the treatment of colorectal cancer (SITC 2024) - "T cell engagers as a modality have gained attraction in solid tumors, but despite the early data that T cells can infiltrate cold CRC tumors with therapies such as Cibisatamab, treatment remains challenging due to poor target specificity and related on-target off-tumor toxicity. We have demonstrated efficacy and safety of Cartography's CB21 TCE in a preclinical setting. Data generated strongly supports clinical development of this CB21 TCE."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • MSI

Cartography Unveils First Pipeline Program Targeting a Highly-Specific and Emerging Colorectal Cancer Antigen in Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Businesswire) - "Cartography Biosciences, Inc...announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually....'CB21 has the potential to be a first and best-in-class molecule and positions Cartography as a leader in targeted LY6G6D therapies as we move our program towards IND in 2025.'"

IND • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor